Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00318331 · ClinicalTrials.gov registry record · Phase 2

Enteral Glutamine in Critical Illness

A Phase 2 study, sponsored by Christiana Care Health Services.

Terminated
Registry status
Phase 2
Development phase
20
Enrollment target

NCT00318331: Clinical Trial Phase 2 study, sponsored by Christiana Care Health Services.

NCT00318331 is a Phase 2 study that was terminated before completion, run by Christiana Care Health Services. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00318331, a Phase 2 study, was terminated before completion, sponsored by Christiana Care Health Services.

TERMINATED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

Glutamine is an amino acid which is rapidly depleted in critical illness. It is used as energy by cells that line the gut, vital for immune system function, and works as an anti-oxidant. Glutamine supplementation has been shown to improve outcomes in ICU patients. We hypothesize that critically ill patients given extra glutamine will have less of an inflammatory response and therefore better outcomes than patients not given extra glutamine. Our study randomizes patients to tube feeding with OR without extra glutamine to see if it affects patient outcomes as well as markers of inflammation.

Interventions

  • DRUG Glutamine

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2006-05
Est. Completion 2007-09
Phase Phase 2
Christiana Care Health Services

82 total trials

Why NCT00318331 stopped before completion

NCT00318331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which Glutamine is the first listed.

NCT00318331 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00318331 about?

NCT00318331 is a clinical study titled "Enteral Glutamine in Critical Illness". Glutamine is an amino acid which is rapidly depleted in critical illness. It is used as energy by cells that line the gut, vital for immune system function, and works as an anti-oxidant. Glutamine supplementation has been shown to improve outcomes in ICU patients. We hypothesize that critically ill ...

What is the current status of trial NCT00318331?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00318331?

The interventions under investigation include: Glutamine (DRUG).

Who is sponsoring clinical trial NCT00318331?

This trial is sponsored by Christiana Care Health Services, which has 82 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00318331's enrollment target sits among peer trials

20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00318331, the US trial registry maintained by the National Library of Medicine. NCT00318331 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.